

Supplementary Material

Supplemental Table S1. Primary and secondary outcomes at 1 year, according to the rhythm on the pre-PCI ECG - patients with prior oral anticoagulation excluded

Outcomes	AF/Flutter (N=369)	Sinus rhythm (N=8321)	Unadjusted		Adjusted*	
			HR (95% CI)	P Value	HR (95% CI)	P Value
Primary and secondary outcomes						
Primary outcome	60 (16.3%)	610 (7.3%)	2.35 (1.80-3.07)	<0.001	1.74 (1.31-2.30)	<0.001
Cardiovascular death	35 (9.5%)	270 (3.2%)	3.04 (2.14-4.32)	<0.001	1.94 (1.33-2.82)	<0.001
Recurrent MI	10 (2.7%)	200 (2.4%)	1.18 (0.62-2.22)	0.617	1.04 (0.54-1.97)	0.915
Cardiogenic shock	14 (3.8%)	150 (1.8%)	2.16 (1.24-3.75)	0.006	1.62 (0.90-2.91)	0.107
Class IV Heart failure	17 (4.6%)	155 (1.9%)	2.60 (1.57-4.29)	<0.001	1.91 (1.14-3.18)	0.013
CVD, MI, CardShock, HF, Stent thrombosis, TVR	73 (19.8%)	900 (10.8%)	1.95 (1.54-2.48)	<0.001	1.53 (1.20-1.97)	<0.001
All-Cause Mortality	41 (11.1%)	322 (3.9%)	2.99 (2.16-4.15)	<0.001	1.88 (1.34-2.66)	<0.001
Stent Thrombosis	5 (1.4%)	164 (2.0%)	0.71 (0.29-1.73)	0.455	0.59 (0.24-1.44)	0.242
Definite stent Thrombosis	4 (1.1%)	115 (1.4%)	0.81 (0.30-2.18)	0.670	0.73 (0.27-2.00)	0.539
Target vessel revascularization	17 (4.6%)	444 (5.3%)	0.90 (0.56-1.47)	0.678	0.84 (0.52-1.38)	0.498
Major bleeding	8 (2.2%)	150 (1.8%)	1.25 (0.61-2.54)	0.541	0.99 (0.48-2.03)	0.981
Safety outcome						
Stroke	6 (1.6%)	75 (0.9%)	1.89 (0.82-4.33)	0.135	1.10 (0.44-2.75)	0.846
TIA	1 (0.3%)	19 (0.2%)	1.24 (0.17-9.27)	0.833	1.04 (0.14-7.85)	0.973
Stroke/TIA	7 (1.9%)	93 (1.1%)	1.77 (0.82-3.82)	0.144	1.11 (0.48-2.57)	0.805
Net risk-benefit risk outcome						
CVD, MI, CardShock, HF, Stroke	63 (17.1%)	656 (7.9%)	2.30 (1.77-2.99)	<0.001	1.67 (1.27-2.20)	<0.001

* Adjusted for age, symptom onset (6-12hrs vs. <6hrs), gender, MI type, current smoking, previous hypertension, previous diabetes, previous MI, previous PCI, proximal lesion, previous stroke and Killip class

Supplemental Table S2. Effect of treatments on primary outcome and components, subgrouped by rhythm on the pre-PCI ECG

Outcomes	Subgroup	Thrombectomy^a	PCI alone^a	HR (95% CI)	P value †
Primary outcome	SR	307/4252 (7.2)	310/4141 (7.5)	0.96 (0.82-1.13)	0.263
	AF	42/218 (19.3)	34/219 (15.5)	1.27 (0.80-2.00)	
CV death	SR	135/4252 (3.2)	139/4141 (3.4)	0.94 (0.74-1.20)	0.542
	AF	23/218 (10.6)	20/219 (9.1)	1.16 (0.63-2.11)	
Recurrent MI	SR	104/4252 (2.4)	100/4141 (2.4)	1.01 (0.77-1.33)	0.568
	AF	7/218 (3.2)	5/219 (2.3)	1.42 (0.45-4.48)	
Cardiogenic shock	SR	75/4252 (1.8)	78/4141 (1.9)	0.93 (0.68-1.28)	0.728
	AF	7/218 (3.2)	9/219 (4.1)	0.78 (0.29-2.10)	
Class IV heart failure	SR	80/4252 (1.9)	77/4141 (1.9)	1.01 (0.74-1.38)	0.433
	AF	14/218 (6.4)	10/219 (4.6)	1.43 (0.63-3.22)	

^aValues are given as no. of events/no. of patients (%).

†P value for interaction is from likelihood ratio test of interaction term, using unadjusted Cox regression model. For abbreviations, see previous tables.

Supplemental Table S3. Primary and secondary outcomes at 1 year, according to use of OAC or antiplatelet drug at discharge in AF/flutter patients

Outcome	OAC^a (N=120)	Antiplatelet drug^a (N=293)	Unadjusted HR (95% CI)	P Value
Primary outcome	21 (17.5%)	32 (10.9%)	1.67 (0.96-2.90)	0.069
Recurrent MI	4 (3.3%)	8 (2.7%)	1.22 (0.37-4.07)	0.741
Major bleeding	8 (6.7%)	5 (1.7%)	4.02 (1.31-12.3)	0.015
Stroke	9 (7.5%)	2 (0.7%)	11.4 (2.46-52.7)	0.002
TIA	1 (0.8%)	0 (0.0%)	-	-
Stroke/TIA	10 (8.3%)	2 (0.7%)	12.7 (2.78-58.0)	0.001